GMAB (GMAB) Stock Price & Analysis
GMAB (GMAB) fell 2.35% to USD 33.6 as of September 8, 2026 at 05:49 UTC, according to Nexqual real-time market data.
GMAB last closed at USD 33.6; the session ranged USD 33.55–34.19 on volume of 1,002,605 shares. Market capitalization is —, with a 52-week range of USD 23.62–35.43 (NMS). Source: Nexqual, September 8, 2026 at 05:49 UTC.
Key Statistics (as of September 8, 2026 at 05:49 UTC)
| Price | USD 33.6 |
|---|---|
| Change | ▼ 2.35% (down) |
| Previous Close | USD 33.6 |
| Open | USD 33.6 |
| Day Range | USD 33.55 – 34.19 |
| 52-Week Range | USD 23.62 – 35.43 |
| Volume | 1,002,605 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (GMAB)
Nexqual's technical model rates GMAB "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:49 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.71 (neutral) |
| vs SMA50 | Above (USD 30.42) |
| MACD | 1.1 (positive) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARGX | argenx SE | USD 1,033.15 | ▼ 2.11% |
| LEGN | Legend Biotech Corporation | USD 21.52 | ▼ 1.69% |
| DNLI | Denali Therapeutics Inc. | USD 22.28 | ▼ 2.49% |
| LKFT | Lakefront Biotherapeutics | USD 28.49 | ▼ 1.11% |
| BBIO | BridgeBio Pharma, Inc. | USD 74.84 | ▼ 2.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:49 UTC. This page is informational and not investment advice.